Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors
Posted inCardiology news Oncology

Beyond Information Delivery: Why Survivorship Care Plans Alone May Not Reduce Cardiovascular Risk in Cancer Survivors

This article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentation improved, counseling did not significantly outperform simple risk assessments.
Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma
Posted inGeneral Surgery news Oncology Pathology & Lab Medicine

Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefining neoadjuvant treatment strategies.
GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients
Posted inCardiology news Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offering a potential biological explanation for differential cardiovascular risks.
Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials
Posted inHematology-Oncology news Oncology

Integrating Patient-Reported Outcomes Significantly Enhances the Reliability of Toxicity Assessments in Cancer Trials

A multinational randomized trial demonstrates that providing oncologists with patient-reported outcome data significantly improves the inter-rater reliability of CTCAE ratings for symptomatic adverse events, addressing a long-standing gap in clinical trial data quality and patient safety monitoring.